Publications by authors named "Yurie Tonai"

Article Synopsis
  • - Scientists identified specific proteins and molecules in the central nervous system (CNS) that can be targeted to create engineered cells for therapy.
  • - They developed synthetic Notch receptors to program T cells to release certain treatments only in the brain, effectively clearing brain tumors without affecting cells in other areas.
  • - The research also found that T cells delivering interleukin-10, an immune-suppressing cytokine, helped reduce symptoms in a mouse model of neuroinflammation, showing potential for targeted treatment strategies.
View Article and Find Full Text PDF

Chimeric antigen receptor (CAR) costimulatory domains derived from native immune receptors steer the phenotypic output of therapeutic T cells. We constructed a library of CARs containing ~2300 synthetic costimulatory domains, built from combinations of 13 signaling motifs. These CARs promoted diverse human T cell fates, which were sensitive to motif combinations and configurations.

View Article and Find Full Text PDF

Overexpressed tumor-associated antigens [for example, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)] are attractive targets for therapeutic T cells, but toxic "off-tumor" cross-reaction with normal tissues that express low levels of target antigen can occur with chimeric antigen receptor (CAR)-T cells. Inspired by natural ultrasensitive response circuits, we engineered a two-step positive-feedback circuit that allows human cytotoxic T cells to discriminate targets on the basis of a sigmoidal antigen-density threshold. In this circuit, a low-affinity synthetic Notch receptor for HER2 controls the expression of a high-affinity CAR for HER2.

View Article and Find Full Text PDF